Heparin-Induced Thrombocytopenia
- 1 November 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Orthopaedic Nursing
- Vol. 26 (6), 383-385
- https://doi.org/10.1097/01.nor.0000300952.80870.ce
Abstract
Each year, 25% of all hospitalized patients are affected by venous thromboembolism, a disease comprising deep vein thrombosis and pulmonary embolism, that is responsible for up to 10% of all inpatient deaths (Alikhan, Peters, Wilmott, Cohen, 2004). Used in both the treatment and the prevention of venous thromboembolism, heparin is administered to more than 12 million patients each year in the United States, making it one of the most widely prescribed medications and the leading intravenous anticoagulant. Heparin-induced thrombocytopenia is an antibody-mediated adverse drug reaction to heparin therapy with potentially life-threatening complications. This article discusses the pathogenesis, diagnosis, and treatment of patients with heparin-induced thrombocytopenia.Keywords
This publication has 12 references indexed in Scilit:
- Heparin-induced thrombocytopenia in intensive care patientsCritical Care Medicine, 2007
- Heparin-Induced ThrombocytopeniaCritical Care Nurse, 2006
- Heparin-induced thrombocytopenia and cardiovascular diseasesAmerican Heart Journal, 2006
- Finding Haystacks Full of NeedlesChest, 2005
- Fatal pulmonary embolism in hospitalised patients: a necropsy reviewJournal of Clinical Pathology, 2004
- Heparin-Induced ThrombocytopeniaArchives of Internal Medicine, 2004
- Heparin-induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2003
- Bioengineering Studies of Periodic External Compression as Prophylaxis Against Deep Vein Thrombosis—Part I: Numerical StudiesJournal of Biomechanical Engineering, 1982
- Arterial thromboembolism in patients receiving systemic heparin therapyJournal of Bone and Joint Surgery, 1977
- TWO NEW FACTORS IN BLOOD COAGULATION—HEPARIN AND PRO-ANTITHROMBINAmerican Journal of Physiology-Legacy Content, 1918